Опубликована: Янв. 1, 2024
Язык: Английский
Cell Cycle, Год журнала: 2025, Номер unknown, С. 1 - 13
Опубликована: Апрель 14, 2025
Cells regulate the expression of cell cycle-related genes, including cyclins essential for mitosis, through transcriptional activity positive transcription elongation factor b (P-TEFb), a complex comprising CDK9, cyclin T, and factors. P-TEFb cooperates with CDK7 to activate RNA polymerase. In response DNA stress, cycle shifts from mitosis repair, triggering arrest activation repair genes. This tight coordination between transcription, progression, stress is crucial maintaining cellular integrity. Cyclin-dependent kinases CDK9 are central both regulation. functions as CDK-activating kinase (CAK), activating other CDKs, while acts critical integrator signals machinery. review elucidates mechanisms by which mitotic process checkpoints, emphasizing their roles in balancing growth, homeostasis, control.
Язык: Английский
Процитировано
0
BioFactors, Год журнала: 2025, Номер 51(3)
Опубликована: Апрель 30, 2025
The G1/S transition is a highly regulated and pivotal checkpoint in the cell cycle, where decides whether to commit DNA replication subsequent division or enter non-dividing state. This serves as critical control point for preventing uncontrolled proliferation maintaining genomic stability. major driving force underlying sequential activation of Cyclin-dependent kinases (CDKs), which by coordinated binding Cyclin partners, well phosphorylation ubiquitin-mediated degradation both partners kinase inhibitors (CKIs). Various E3 ligase families govern timely these regulatory proteins, with their activity intricately controlled events. coordination enables cells efficiently translate environmental cues molecular signaling inputs determine fate. We explore evolution three distinct models describing transition, highlighting how traditional linear model being challenged recent paradigm shifts conflicting findings. These advances reveal emerging complexity unresolved questions field, particularly regarding latest insights into ubiquitination-dependent integrate contemporary transition.
Язык: Английский
Процитировано
0
Trends in Cell Biology, Год журнала: 2025, Номер unknown
Опубликована: Май 1, 2025
Язык: Английский
Процитировано
0
International Journal of Biological Macromolecules, Год журнала: 2024, Номер unknown, С. 136807 - 136807
Опубликована: Окт. 1, 2024
Язык: Английский
Процитировано
3
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, Год журнала: 2024, Номер 1879(5), С. 189174 - 189174
Опубликована: Авг. 30, 2024
Язык: Английский
Процитировано
2
Methods in molecular biology, Год журнала: 2024, Номер unknown, С. 263 - 273
Опубликована: Янв. 1, 2024
Язык: Английский
Процитировано
0
Опубликована: Янв. 1, 2024
Download This Paper Open PDF in Browser Add to My Library Share: Permalink Using these links will ensure access this page indefinitely Copy URL DOI
Язык: Английский
Процитировано
0
MAEDICA – a Journal of Clinical Medicine, Год журнала: 2024, Номер 19(2)
Опубликована: Июнь 15, 2024
Onset and progression of malignant tumors is a multistep process including variety gross chromosomal specific genes' deregulation. Among oncogenes that are frequently altered in solid also hematological malignancies, the C-myc (gene locus: 8q24.21) plays pivotal role. proto-oncogene encoding for nuclear phosphoprotein implicated cell cycle progression, apoptosis cellular differentiation transformation.
Язык: Английский
Процитировано
0
bioRxiv (Cold Spring Harbor Laboratory), Год журнала: 2024, Номер unknown
Опубликована: Ноя. 15, 2024
The combination of CDK4/6 inhibitors (CDK4/6i) and endocrine therapy has revolutionized treatment for hormone receptor-positive (HR+) metastatic breast cancer. However, the emergence resistance in most patients often leads to discontinuation with no consensus on effective second-line therapies. therapeutic benefits maintaining CDK4/6i or incorporating CDK2 (CDK2i) after disease progression remain unclear. Here, we demonstrate that sustained therapy, either alone combined CDK2i, significantly suppresses growth drug-resistant HR
Язык: Английский
Процитировано
0
Frontiers in Immunology, Год журнала: 2024, Номер 15
Опубликована: Ноя. 27, 2024
The treatment of multiple myeloma (MM) has significantly advanced; however, the underlying genetic mechanisms remain elusive. Clonal events and alterations are recognized as pivotal in pathogenesis MM. It is now understood that a multitude gene mutations, including those affecting RAS,
Язык: Английский
Процитировано
0